Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 03:55PM ET
0.4300
Dollar change
+0.0500
Percentage change
13.16
%
Index- P/E0.34 EPS (ttm)1.28 Insider Own52.23% Shs Outstand4.97M Perf Week-6.72%
Market Cap3.72M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.13M Perf Month-29.51%
Income3.06M PEG- EPS next Q- Inst Own4.33% Short Float / Ratio3.00% / 8.71 Perf Quarter-46.80%
Sales23.79M P/S0.16 EPS this Y- Inst Trans-0.96% Short Interest0.12M Perf Half Y-54.26%
Book/sh1.12 P/B0.38 EPS next Y- ROA11.25% Target Price2.00 Perf Year-57.43%
Cash/sh0.27 P/C1.60 EPS next 5Y- ROE56.40% 52W Range0.37 - 1.78 Perf YTD-62.61%
Dividend- P/FCF- EPS past 5Y55.67% ROI19.01% 52W High-75.84% Beta1.07
Dividend %- Quick Ratio2.56 Sales past 5Y1609.32% Gross Margin92.58% 52W Low16.82% ATR0.05
Employees13 Current Ratio2.56 Sales Q/Q-100.00% Oper. Margin13.48% RSI (14)34.99 Volatility12.02% 9.57%
OptionableNo Debt/Eq0.72 EPS Q/Q58.78% Profit Margin12.88% Rel Volume6.16 Prev Close0.38
ShortableYes LT Debt/Eq0.66 Earnings- Payout- Avg Volume14.23K Price0.43
Recom3.00 SMA20-16.46% SMA50-29.39% SMA200-52.29% Volume86,719 Change13.16%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
04:01PM Loading…
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
04:01PM Loading…
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
05:57PM Loading…
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
04:00PM
01:36PM
12:15PM
09:10AM
Dec-14-21 09:00PM
01:53PM
12:45PM
10:12AM
09:34AM
Dec-13-21 10:00PM
06:57PM
05:15PM
04:30PM
03:38PM
01:20PM
10:15AM
Dec-12-21 09:00PM
Dec-10-21 05:36PM
Dec-08-21 12:55PM
Dec-07-21 09:00PM
04:37PM
Dec-03-21 08:35PM
06:13PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CBI USA, Inc.10% OwnerDec 15Buy1.603,400,0005,440,0004,218,299Dec 19 04:54 PM